Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Lorus Therapeutics announces that the European Medicines Agency (EMEA) has granted the orphan drug designation to LOR-2040 for the treatment of Acute Myeloid Leukemia (AML)
July 11th, 2008
Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, announced that its lead Clinical drug, LOR-2040, has been granted Orphan Drug status for the treatment of Acute Myeloid Leukemia (AML) by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA). For a medicinal product to be designated as an orphan medicinal product in the European Union (EU), the sponsor must establish that a satisfactory method of treatment, which has been authorized in the European Community,...
Source: Health Business Week (2008-07-11)
|
